HCW9218

DRUG3 trials

Sponsors

Haider Mahdi, ImmunityBio, Inc., Masonic Cancer Center, University of Minnesota

Conditions

Advanced Pancreatic CarcinomaOvarian CancerSolid Tumor

Phase 1

HCW9218 for Advanced Pancreatic Cancer

CompletedNCT05304936

ImmunityBio, Inc.Advanced Pancreatic Carcinoma

Start: 2022-10-17End: 2025-02-15Updated: 2026-04-15

HCW9218 in Select Advanced Solid Tumors

CompletedNCT05322408

Masonic Cancer Center, University of MinnesotaSolid Tumor

Start: 2022-04-01End: 2025-02-28Updated: 2025-11-05

Phase 2

Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer

WithdrawnNCT05145569

Haider MahdiOvarian Cancer

Start: 2024-05-10End: 2028-01-31Updated: 2025-01-01

Related Papers

767 Pre-clinical and first-in-human studies of HCW9218, a bifunctional TGF-β antagonist/IL-15 protein complex, in advanced solid tumors

Regular and Young Investigator Award Abstracts2023-10-312 citations

Abstract 4441: Bifunctional immunotherapeutic HCW9218 facilitates recruitment of immune cells from tumor draining lymph nodes to promote antitumor activity and enhance checkpoint blockade efficacy in solid tumors

Cancer Research2023-04-042 citations

724 A phase I study of HCW9218, a bifunctional TGF-β Antagonist/IL-15 protein complex, in advanced solid tumors

Regular and Young Investigator Award Abstracts2022-11-011 citations